LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "monocytic aml" as a keyword



Abstract 2372: ATG-102, a novel LILRB4 x CD3 T cell engager, targeting two nonoverlapping epitopes of LILRB4, for the treatment of monocytic AML

Sign Up to like & get
recommendations! Published in 2024 at "Cancer Research"

DOI: 10.1158/1538-7445.am2024-2372

Abstract: Background: Acute myeloid leukemia (AML) is the most common acute leukemia in adults, and the treatment of AML, especially monocytic AML subtypes still has a poor outcome. T cell engagers (TCE) have been well used… read more here.

Keywords: monocytic aml; cd3; lilrb4; cell ... See more keywords

PCYT1A Is a Metabolic Vulnerability in Monocytic Acute Myeloid Leukemia

Sign Up to like & get
recommendations! Published in 2024 at "Blood"

DOI: 10.1182/blood-2024-202832

Abstract: Acute myeloid leukemia (AML) is a highly heterogeneous blood cancer with unique morphologic and genomic characteristics. Several genetic aberrations, such as TP53 mutations (TP53-MT) and MLL (KMT2A) rearrangements (MLL-r), are associated with inferior outcomes. The… read more here.

Keywords: monocytic aml; mll aml; aml; pcyt1a ... See more keywords

Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML

Sign Up to like & get
recommendations! Published in 2024 at "Blood"

DOI: 10.1182/blood-2024-204762

Abstract: Introduction: Venetoclax in combination with Azacitidine (VA) is the first-line induction regimen recommended by NCCN guidelines for AML patients who are ineligible or decline intensive chemotherapy. However, studies have identified multiple mechanisms developing resistance to… read more here.

Keywords: vac group; monocytic aml; aml; group ... See more keywords

ASAH1-mediated sphingolipid metabolic reprogramming in venetoclax resistance of AML: beyond the monocytic phenotypes.

Sign Up to like & get
recommendations! Published in 2025 at "BMC cancer"

DOI: 10.1186/s12885-025-15272-9

Abstract: Venetoclax (VEN) in combination with hypomethylating agents has emerged as a pivotal therapy for elderly acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy. However, monocytic AML exhibit greater resistance to VEN-based regimens compared to… read more here.

Keywords: resistance; monocytic aml; sphingolipid metabolism; aml ... See more keywords